Tag: MONOGRAPH

  • CHIR-99021

    Highly selective aminopyrimidine glycogen synthase kinase 3 (GSK-3) inhibitor and canonical Wnt/beta-catenin signaling pathway activator

    A potent, orally active aminopyrimidine developed at Chiron Corporation as a selective dual-isoform GSK-3 inhibitor, distinguished by sub-10-nanomolar potency against both GSK-3alpha and GSK-3beta with greater than 500-fold selectivity over closely related kinases, and now the most widely deployed small-molecule Wnt pathway activator in stem cell biology, directed differentiation, chemical reprogramming, and regenerative medicine research.

    Abstract

    CHIR-99021 (CT99021, laduviglusib) is a synthetic aminopyrimidine derivative and the most potent and selective small-molecule inhibitor of glycogen synthase kinase 3 (GSK-3) in current research and clinical use, with half-maximal inhibitory concentrations of approximately 10 nM against GSK-3alpha and 6.7 nM against GSK-3beta. The compound was developed at Chiron Corporation in the early 2000s as part of a medicinal chemistry program targeting GSK-3 for the treatment of type 2 diabetes mellitus, and was first characterized in the seminal Ring et al. (2003) publication demonstrating that selective GSK-3 inhibition potentiates insulin-stimulated glucose transport and utilization both in vitro and in vivo [1]. CHIR-99021 achieves its selectivity through an aminopyrimidine scaffold bearing a 2,4-dichlorophenyl substituent and a 5-methyl-1H-imidazol-2-yl group, producing greater than 500-fold selectivity for GSK-3 over 20 closely related protein kinases and greater than 800-fold selectivity across a broader panel of 23 additional enzymes and 22 receptors [1, 2].

    The principal pharmacological consequence of GSK-3 inhibition by CHIR-99021 is stabilization of cytoplasmic beta-catenin through prevention of its phosphorylation-dependent proteasomal degradation. Accumulated beta-catenin translocates to the nucleus and transactivates Wnt-responsive genes through interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) family transcription factors, producing a pharmacological activation of the canonical Wnt/beta-catenin signaling pathway that is functionally equivalent to Wnt ligand stimulation. This mechanism has made CHIR-99021 the standard small-molecule Wnt pathway activator in stem cell biology and regenerative medicine, where it is deployed in the “2i” naive pluripotency medium (in combination with the MEK inhibitor PD0325901) for maintenance of mouse embryonic stem cells, in directed differentiation protocols for the generation of cardiomyocytes, neural progenitor cells, pancreatic beta cells, and hematopoietic progenitors from human pluripotent stem cells, and in chemical reprogramming cocktails for the generation of induced pluripotent stem cells from somatic cells without genetic manipulation [3, 4, 5].

    The compound has also been identified as a component of chemical cocktails for direct reprogramming of fibroblasts to cardiomyocytes and to chemically induced pluripotent stem cells (CiPSCs) [9, 10].

    Pharmacokinetic characterization in rodents demonstrates oral bioavailability sufficient for in vivo efficacy studies, though the compound is used predominantly as an in vitro research tool and has not been independently advanced through human pharmacokinetic characterization outside the FX-322 combination formulation. Safety considerations include the potential for off-target effects on dopaminergic neurotransmission, with ex vivo studies demonstrating that CHIR-99021 causes inactivation of tyrosine hydroxylase and depletion of dopamine in rat brain striatum, a finding that warrants consideration in the design of in vivo studies and in the interpretation of central nervous system effects [11]. The compound is supplied as a research-grade preparation by multiple chemical suppliers at greater than 98 percent purity; investigators should confirm identity and purity on every lot and should prepare stock solutions in dimethyl sulfoxide owing to the limited aqueous solubility of the free base form.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Trimetazidine

    Piperazine-derived partial fatty acid oxidation inhibitor (p-FOX) and metabolic modulator of myocardial energy substrate utilization

    A cytoprotective anti-ischemic piperazine developed by Laboratoires Servier as the first metabolic modulator of cardiac energy substrate preference, distinguished from hemodynamic antianginal agents by its oxygen-sparing shift from long-chain fatty acid beta-oxidation to glucose oxidation through selective inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

    Abstract

    Trimetazidine (1-(2,3,4-trimethoxybenzyl)piperazine) is a metabolic anti-ischemic agent developed by Laboratoires Servier in the late 1960s and first marketed in France in 1978 under the trade name Vastarel. It is registered in approximately 100 countries for the treatment of stable angina pectoris as add-on therapy to hemodynamic antianginal agents and, in certain jurisdictions, for symptomatic management of vertigo, tinnitus, and visual disturbance of vascular origin, although the European Medicines Agency restricted the latter indications following a 2012 Article 31 referral. The compound is not approved by the United States Food and Drug Administration and is not available in the United States, Canada, or the United Kingdom.

    The molecular mechanism of trimetazidine is metabolic rather than hemodynamic. The compound selectively inhibits the mitochondrial long-chain 3-ketoacyl coenzyme A thiolase (3-KAT, also designated mitochondrial trifunctional protein thiolase), the terminal enzyme in the beta-oxidation spiral of long-chain fatty acids, with an IC50 of approximately 75 nanomolar as originally reported by Kantor et al. (2000) in isolated working rat hearts, although subsequent work by MacInnes et al. (2003) using purified enzyme preparations challenged the direct enzymatic inhibition and proposed alternative upstream targets. The functional consequence of 3-KAT inhibition is a shift in myocardial energy substrate preference from fatty acid oxidation (which consumes more oxygen per mole of ATP generated) to glucose oxidation (which is approximately 12 percent more oxygen-efficient per unit of ATP), thereby preserving myocardial high-energy phosphate pools under ischemic conditions without altering heart rate, blood pressure, coronary blood flow, or rate-pressure product. The compound additionally increases pyruvate dehydrogenase activity, reduces intracellular calcium overload, attenuates reactive oxygen species generation, decreases neutrophil infiltration in ischemic myocardium, and preserves intracellular pH homeostasis during ischemia and reperfusion.

    The clinical evidence base for trimetazidine in stable angina pectoris is extensive. Multiple randomized controlled trials, including the TRIMPOL-I, TRIMPOL-II, and VASCO-angina studies, have demonstrated that trimetazidine as add-on therapy to beta-blockers, calcium channel blockers, or long-acting nitrates produces statistically significant improvements in total exercise duration, time to 1 mm ST-segment depression, and weekly angina attack frequency compared to placebo. The 2024 European Society of Cardiology guidelines for chronic coronary syndromes assign trimetazidine a Class IIb, Level of Evidence B recommendation as add-on antianginal therapy in patients with inadequate symptom control, a downgrade from the prior Class IIa designation that has been criticized by some experts as inconsistent with the available trial evidence. A separate and growing literature supports benefit in heart failure with reduced ejection fraction (HFrEF): multiple meta-analyses (Gao et al. 2011, Zhang et al. 2012, Weng et al. 2024) pooling data from over 1,500 patients have reported mean improvements in left ventricular ejection fraction of 6 to 7.5 percentage points, reductions in cardiac hospitalization (relative risk 0.43), and reductions in all-cause mortality (relative risk 0.47), leading to inclusion of trimetazidine in the 2021 ESC heart failure guidelines at a Class IIb level for relief of persistent angina in heart failure patients.

    The compound is generally well tolerated; the principal adverse events are gastrointestinal disturbance (nausea, epigastric discomfort), asthenia, headache, and dizziness. The most clinically significant safety signal is the induction of reversible parkinsonian symptoms (rest tremor, bradykinesia, gait disturbance, rigidity) in a small fraction of patients, predominantly elderly, on prolonged therapy. This signal prompted the 2012 EMA Article 31 referral that resulted in new contraindications (Parkinson disease, parkinsonian symptoms, tremor, restless leg syndrome, severe renal impairment) and restriction of indications. Symptoms resolve in most patients within weeks to months of drug discontinuation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Efimosfermin

    Long-acting Fc-fusion fibroblast growth factor 21 (FGF21) analog with direct antifibrotic, anti-steatotic, and metabolic regulatory activity

    An engineered, once-monthly IgG1-Fc-fused FGF21 analog developed by Novartis and advanced through Boston Pharmaceuticals and GSK for the treatment of metabolic dysfunction-associated steatohepatitis, distinguished from other FGF21 analogs by a 21-day pharmacokinetic half-life that permits monthly subcutaneous dosing and by Phase 2 evidence of fibrosis reversal and MASH resolution in patients with moderate-to-advanced hepatic fibrosis.

    Abstract

    Efimosfermin alfa (formerly LLF580 under Novartis origination, subsequently designated BOS-580 under Boston Pharmaceuticals development, and now GSK-6519754 following acquisition by GSK plc) is a genetically engineered, long-acting analog of human fibroblast growth factor 21 (FGF21), a hepatokine and adipokine that regulates hepatic lipid oxidation, adipose tissue glucose uptake, triglyceride metabolism, and inflammatory signaling through formation of a ternary complex with the transmembrane tyrosine kinase FGF receptor 1c (FGFR1c) and the obligate co-receptor beta-klotho (KLB). The molecule is a homodimeric fusion protein in which two copies of a stabilized FGF21 variant are fused at their N-termini to the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). The FGF21 domain is further stabilized by the introduction of a non-native disulfide bond and point mutations that increase proteolytic resistance, together producing a pharmacokinetic half-life of approximately 21 days in humans and enabling subcutaneous administration once every four weeks. This dosing interval distinguishes efimosfermin from the weekly-dosed FGF21 analogs efruxifermin (Akero Therapeutics) and pegozafermin (89bio), which require subcutaneous injection every one to two weeks.

    In May 2025, GSK plc completed acquisition of efimosfermin from Boston Pharmaceuticals for 1.2 billion United States dollars upfront and up to 800 million dollars in milestone payments, with tiered royalties owed to Novartis Pharma AG. The compound has received United States Food and Drug Administration Breakthrough Therapy Designation and European Medicines Agency Priority Medicines (PRIME) Designation for the treatment of MASH. Phase 3 development (the ZENITH program) commenced in December 2025, with a potential first launch projected for 2029. GSK has indicated development plans in both MASH (including compensated cirrhosis) and alcohol-related liver disease (ALD), with potential for combination therapy with GSK’990, a complementary hepatology pipeline candidate. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Elinzanetant

    Dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist for non-hormonal treatment of menopausal vasomotor symptoms

    A non-hormonal, orally bioavailable dual NK1/NK3 receptor antagonist developed through GlaxoSmithKline, NeRRe Therapeutics, KaNDy Therapeutics, and Bayer for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, distinguished from selective NK3 antagonists by concurrent blockade of substance P signaling and consequent additive benefits on sleep, mood, and thermoregulatory dysregulation.

    Abstract

    Elinzanetant (Lynkuet; BAY3427080; formerly NT-814 and GSK1144814) is a potent and selective dual antagonist of the neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors, developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause and with endocrine therapy for hormone receptor-positive breast cancer. Elinzanetant is the first and only approved dual NK1/NK3 receptor antagonist, mechanistically distinct from fezolinetant (Veozah), which acts solely on the NK3 receptor. The dual mechanism targets kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus, where neurokinin B (NKB) acting through NK3 receptors initiates thermoregulatory dysregulation responsible for hot flashes, and substance P (SP) acting through NK1 receptors amplifies KNDy neuronal activity and contributes to sleep disruption, mood disturbance, and peripheral vasodilation. By antagonizing both receptor subtypes, elinzanetant addresses the composite symptom burden of menopause rather than isolated hot flash frequency alone. The compound exhibits high affinity for human NK1 receptors (pKi 8.7 to 10.2) and NK3 receptors (pKi 8.0 to 8.8), with greater than 300-fold selectivity for NK1 and greater than 100-fold selectivity for NK3 over off-target receptors. Pharmacokinetics are characterized by rapid oral absorption (median Tmax approximately 1 hour), absolute oral bioavailability of 52 percent, extensive plasma protein binding (99.7 percent), a large volume of distribution (137 L), and a long elimination half-life of approximately 45 hours that supports once-daily dosing. Metabolism is predominantly CYP3A4-mediated, producing three active metabolites with comparable NK1/NK3 potency at approximately 39 percent of parent plasma exposure. Excretion is predominantly fecal (90 percent as metabolites). The clinical evidence base comprises the OASIS Phase 3 program: OASIS 1 and OASIS 2 (12-week placebo-controlled studies in approximately 400 postmenopausal women each), OASIS 3 (52-week long-term study in 628 women), and OASIS 4 (12-week study in women receiving breast cancer endocrine therapy). All trials met primary endpoints, demonstrating statistically significant and clinically meaningful reductions in VMS frequency and severity at weeks 4 and 12, with onset of effect as early as week 1. Secondary endpoints showed significant improvements in sleep disturbances, menopause-related quality of life, and mood. Long-term efficacy was maintained through 52 weeks in OASIS 3 with no signal of hepatotoxicity, endometrial hyperplasia, or endometrial malignancy. The most common adverse events are headache (7.8 percent) and fatigue (5 percent). Elinzanetant is contraindicated in pregnancy, in severe hepatic impairment, and with concomitant strong CYP3A4 inhibitors. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • GT20029

    Topical proteolysis-targeting chimera (PROTAC) androgen receptor degrader

    A first-in-class topical PROTAC androgen receptor degrader developed by Kintor Pharmaceutical for androgenetic alopecia and acne vulgaris, distinguished from conventional antiandrogen therapies by catalytic, substoichiometric receptor protein elimination through the ubiquitin-proteasome system with negligible systemic exposure.

    Abstract

    GT20029 is a small-molecule proteolysis-targeting chimera (PROTAC) designed for topical application to skin and scalp, representing the first PROTAC compound to enter and complete clinical trials via the topical route of administration. Developed by Suzhou Kintor Pharmaceutical Ltd. on a proprietary PROTAC platform employing a novel cereblon (CRBN) E3 ubiquitin ligase recruiting element (the TD-106 scaffold), GT20029 functions as a bifunctional molecular bridge: one pharmacophore engages the androgen receptor (AR) ligand-binding domain, a chemical linker spans the two recruiting elements, and a second pharmacophore recruits the CRBN-containing Cullin-RING E3 ubiquitin ligase complex, resulting in polyubiquitination and proteasomal degradation of the AR protein [1, 2]. The catalytic mechanism permits each GT20029 molecule to cycle through multiple rounds of AR degradation, enabling pharmacologically effective AR elimination at low topical concentrations. In preclinical dihydrotestosterone (DHT)-induced mouse models, GT20029 significantly promoted hair regrowth and reversed follicular miniaturization; in testosterone propionate-induced hamster flank organ models, it significantly inhibited sebaceous gland enlargement, supporting the dual indication development for androgenetic alopecia (AGA) and acne vulgaris [3].

    Phase I clinical trials were completed in both China (92 subjects) and the United States (123 subjects) as randomized, double-blind, placebo-controlled studies with single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. GT20029 demonstrated excellent safety and tolerability across all dose levels, with no systemic exposure above the lower limit of quantitation (0.003 ng/mL) in the SAD cohort and maximal plasma concentrations not exceeding 0.015 ng/mL after 14 days of continuous topical application in the MAD cohort, confirming that the compound acts locally with negligible systemic absorption [3]. The Phase II trial for AGA enrolled 180 male patients with Hamilton-Norwood grade IIIv to V pattern hair loss across 12 centers in China in a multicenter, randomized, double-blind, placebo-controlled design. Patients received GT20029 solution at 0.5% or 1.0% concentration, applied once daily (QD) or twice weekly (BIW), for 12 weeks. The primary endpoint was the change from baseline in non-vellus target area hair count (TAHC). The 0.5% QD group demonstrated an increase of 16.80 hairs per square centimeter, 6.69 hairs per square centimeter greater than placebo (P less than 0.05); the 1.0% BIW group demonstrated an increase of 11.94 hairs per square centimeter, 7.36 hairs per square centimeter greater than placebo (P less than 0.05) [4, 5]. Target area hair width also improved significantly in the 1.0% BIW group versus placebo. No adverse sexual events were observed in any treatment group, distinguishing GT20029 from systemic 5-alpha-reductase inhibitors. The Phase II trial for acne vulgaris, conducted across 10 centers in China, also met its primary endpoint for total lesion count reduction (excluding nodules) at the 0.5% QD dose (P = 0.01 versus placebo), with both 0.5% and 1.0% QD groups achieving highly significant reductions in inflammatory lesion counts (P less than 0.01) [6].

    On the basis of these results, Kintor has advanced GT20029 into Phase III clinical trials for male AGA in China and has initiated Phase II trials in the United States. The compound is not yet registered in any jurisdiction. The chemical structure of GT20029 has not been publicly disclosed; the molecular formula, molecular weight, and Chemical Abstracts Service registry number are not available in the public domain. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • HU6

    Liver-targeted prodrug of 2,4-dinitrophenol functioning as a controlled metabolic accelerator through mitochondrial uncoupling via adenine nucleotide translocase activation

    A first-in-class controlled metabolic accelerator developed by Rivus Pharmaceuticals as a liver-targeted prodrug of 2,4-dinitrophenol, designed to exploit mitochondrial uncoupling for the treatment of metabolic dysfunction-associated steatohepatitis, obesity-related heart failure with preserved ejection fraction, and related cardiometabolic disorders while mitigating the systemic toxicity historically associated with the parent uncoupler.

    Abstract

    HU6 (dinifedriton; 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole; CAS 2231311-68-3) is a first-in-class controlled metabolic accelerator (CMA) developed by Rivus Pharmaceuticals as an oral prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP). The compound is designed to undergo hepatic bioactivation to release DNP within the liver, thereby increasing proton leak across the inner mitochondrial membrane via activation of the adenine nucleotide translocase (ANT) channel. This controlled mitochondrial uncoupling increases substrate oxidation, preferentially consuming hepatic and systemic fat stores while reducing reactive oxygen species production and preserving lean skeletal muscle mass. By restricting DNP release to the hepatic first-pass compartment and minimizing systemic peak concentrations, HU6 achieves a substantially wider therapeutic index than the parent uncoupler while retaining its metabolic efficacy.

    The scientific foundation for HU6 derives from the seminal work of Perry et al. (2015), published in Science, demonstrating that a controlled-release mitochondrial protonophore (CRMP) formulation of DNP reversed diabetes, hypertriglyceridemia, hepatic steatosis, and liver fibrosis in rat models of metabolic syndrome and nonalcoholic steatohepatitis (NASH) without systemic toxicity [1]. This proof of concept was extended to dysmetabolic nonhuman primates by Goedeke et al. (2019), who reported that CRMP produced 20 to 30 percent reductions in fasting plasma triglycerides and low-density lipoprotein cholesterol with concurrent resolution of hepatic steatosis [2]. Rivus Pharmaceuticals was founded in 2019 to advance these findings into clinical development, selecting HU6 as the lead clinical candidate from a portfolio of controlled metabolic accelerator assets.

    Three Phase 2 clinical trials have been completed or are in progress. The Phase 2a HuMAIN trial in 66 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) met its primary endpoint of body weight reduction (2.86 kg versus placebo over 19 weeks), with fat-selective weight loss preserving skeletal muscle mass and producing significant improvements in left ventricular ejection fraction (3.76 percent) and end-systolic volume; results were published in JAMA Cardiology [4, 5]. The Phase 2 M-ACCEL trial in 228 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 to F3 demonstrated statistically significant liver fat reductions of 27.0 to 31.2 percent versus 6.7 percent with placebo over 26 weeks, with approximately 50 to 58 percent of treated patients achieving the clinically meaningful threshold of 30 percent or greater liver fat reduction associated with MASH resolution and fibrosis improvement [6].

    Across all three trials, HU6 demonstrated a favorable safety profile with no treatment-related serious adverse events in a cumulative safety database exceeding 500 patients. The most commonly reported treatment-emergent adverse events were flushing (32 percent in early trials, reduced in later formulations), diarrhea (25 percent), and palpitations (12 percent), with discontinuation rates due to adverse events below 5 percent. Gastrointestinal adverse event rates in the M-ACCEL trial were comparable to placebo (14 versus 16 percent). The compound is currently advancing through the AMPLIFY Phase 2 trial for MASH with plans for late-stage clinical development. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ISX-9

    Isoxazole-based small molecule neurogenic agent with Wnt/beta-catenin pathway activation and GPR68 agonism

    A synthetic isoxazole carboxamide identified through phenotypic screening for neuronal cell fate activation, distinguished by calcium-dependent MEF2 de-repression, NeuroD1 induction, Wnt/beta-catenin signaling through Axin1/LRP6 modulation, and proneurogenic activity in the adult hippocampus with demonstrated cognitive enhancement in rodent behavioral models.

    Abstract

    ISX-9 (Isoxazole 9; N-cyclopropyl-5-(thiophen-2-yl)isoxazole-3-carboxamide; CAS 832115-62-5) is a synthetic small molecule originally identified in a high-throughput phenotypic screen for compounds that activate neuronal cell fate in adult neural stem/progenitor cells, reported by Schneider et al. in 2008 in Nature Chemical Biology [1]. The compound triggers robust neuronal differentiation through a calcium-dependent signaling cascade: ISX-9 induces calcium influx via voltage-gated calcium channels and N-methyl-D-aspartate (NMDA) receptors, which activates calcium/calmodulin-dependent protein kinase II (CaMKII), promotes phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5), and thereby de-represses myocyte-enhancer factor 2 (MEF2)-dependent transcription of neuronal genes including NeuroD1 [1, 2]. Subsequent mechanistic characterization identified ISX-9 as a potent activator of the Wnt/beta-catenin signaling pathway through promotion of the association between low-density lipoprotein receptor-related protein 6 (LRP6) and Axin1, resulting in beta-catenin stabilization and upregulation of Wnt target genes [3]. A parallel line of investigation established ISX-9 as a ligand of GPR68 (OGR1), a proton-sensing G protein-coupled receptor expressed in hippocampal neural stem cells, providing a molecular target that links the proneurogenic activity to extracellular pH sensing in the neurogenic niche [4].

    In vivo, ISX-9 crosses the blood-brain barrier and promotes neurogenesis in the subgranular zone of the hippocampal dentate gyrus in adult mice and rats. The compound has been investigated across a surprisingly broad range of preclinical applications beyond hippocampal neurogenesis: protection against methamphetamine relapse through modulation of abstinence-induced neurogenesis in the dentate gyrus [5]; induction of enteroendocrine cell differentiation in mouse and human intestinal organoids through upregulation of neurogenin 3 (Ngn3), NeuroD1, and Pax4 [6]; activation of Wnt/beta-catenin-dependent hair follicle cycling and hair regrowth in C57BL/6J mice [3]; and, most recently, neuroprotection and cognitive rescue in the 5xFAD transgenic mouse model of Alzheimer’s disease through Wnt/beta-catenin pathway activation in hippocampal neurons [7].

    ISX-9 has not entered human clinical trials. No human pharmacokinetic, safety, or efficacy data exist. The compound remains a research tool, albeit one with an expanding preclinical evidence base across neurodegenerative, addiction, regenerative, and endocrine lineage specification applications. Investigators should note that ISX-9 exerts differential effects on distinct progenitor populations: it promotes neuronal differentiation of neural stem/progenitor cells but is cytotoxic to oligodendrocyte precursor cells and inhibits angiogenic tube formation in endothelial progenitor cells at comparable concentrations [8]. This cell-type specificity has implications for interpretation of in vivo effects and for combination research in central nervous system injury models where multiple progenitor populations contribute to repair. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • LDN-193189

    Selective bone morphogenetic protein (BMP) type I receptor kinase inhibitor targeting ALK2 and ALK3

    A pyrazolopyrimidine-scaffold small molecule derived from dorsomorphin structure-activity optimization, selectively inhibiting BMP type I receptor kinases ALK2 and ALK3 at low-nanomolar potency with 200-fold selectivity over TGF-beta signaling, and widely adopted as a research tool for BMP pathway dissection, directed stem cell differentiation, and preclinical modeling of fibrodysplasia ossificans progressiva and diffuse intrinsic pontine glioma.

    Abstract

    LDN-193189 (DM-3189; CAS 1062368-24-4) is a cell-permeable, small-molecule inhibitor of bone morphogenetic protein (BMP) type I receptor serine/threonine kinases, developed through structure-activity relationship optimization of dorsomorphin at the Brigham and Women’s Hospital and Harvard Medical School laboratories of Paul B. Yu. The compound inhibits activin receptor-like kinase 2 (ALK2, also designated ACVR1) with an IC50 of approximately 5 nM and activin receptor-like kinase 3 (ALK3, also designated BMPR1A) with an IC50 of approximately 30 nM, while exhibiting approximately 200-fold selectivity for BMP receptors over the transforming growth factor-beta (TGF-beta) type I receptor ALK5 and negligible activity against ALK4 and ALK7 at concentrations below 500 nM. The mechanism of action involves competitive binding at the ATP-binding pocket of BMP type I receptor kinases, preventing receptor autophosphorylation and blocking downstream phosphorylation of the canonical signaling effectors Smad1, Smad5, and Smad8. In addition to canonical Smad pathway inhibition, LDN-193189 suppresses BMP-induced non-canonical signaling through the p38 mitogen-activated protein kinase (MAPK) and Akt (protein kinase B) pathways, providing broader coverage of BMP-dependent intracellular signaling than Smad-selective interventions alone.

    The compound originated from the 2008 Cuny, Yu, and colleagues structure-activity relationship study that optimized the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin, a compound itself discovered in 2008 by Yu et al. through a phenotypic zebrafish embryo screen of approximately 7,500 bioactive compounds for agents that could dorsalize the developing embryo and thereby phenocopy loss-of-function mutations in the BMP signaling pathway. Dorsomorphin, while the first small-molecule BMP pathway inhibitor identified, exhibited substantial off-target activity against AMP-activated protein kinase (AMPK), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor (PDGFR), limiting its utility as a selective BMP pathway probe. LDN-193189 retained the central pyrazolopyrimidine core but incorporated a quinoline moiety and a piperazinylphenyl substituent that conferred markedly improved potency and selectivity for BMP type I receptors over the off-target kinases that compromised dorsomorphin’s pharmacological profile.

    LDN-193189 has become one of the most widely used pharmacological tools for interrogating BMP signaling in developmental biology, stem cell biology, and disease modeling. In stem cell biology, the compound is a core component of the dual SMAD inhibition protocol (in combination with the TGF-beta/Activin/Nodal inhibitor SB431542) developed by Chambers et al. (2009) for the efficient directed differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) toward neuroectodermal and neural progenitor fates, a protocol that has become the standard method for generating central nervous system neurons from human pluripotent stem cells. In disease modeling, the compound has been extensively characterized in preclinical models of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder caused by gain-of-function mutations in the ACVR1/ALK2 gene that produce constitutive BMP pathway activation and progressive heterotopic ossification of soft tissues. Treatment of mice expressing constitutively active ALK2 with LDN-193189 reduced heterotopic bone formation in the landmark Yu et al. (2008) Nature Medicine study. The compound has also demonstrated preclinical efficacy in orthotopic xenograft models of diffuse intrinsic pontine glioma (DIPG) harboring ACVR1 mutations, extending survival in treated animals. Additional research applications span iron metabolism and hepcidin regulation (through BMP6-dependent Smad signaling in hepatocytes), pulmonary arterial hypertension modeling, chondrogenesis and osteogenesis research, and cancer biology.

    LDN-193189 has not entered human clinical trials and is not a registered medicine in any jurisdiction. The compound is classified as a research tool and is supplied by multiple commercial vendors (Selleck Chemicals, MedChemExpress, Cayman Chemical, Tocris, Sigma-Aldrich, Stemgent/REPROCELL, and others) as the free base or hydrochloride salt at greater than 98 percent purity. In vivo pharmacokinetic characterization in mice has demonstrated oral bioavailability and brain penetration sufficient for central nervous system target engagement, though metabolic liabilities including aldehyde oxidase-dependent metabolism and generation of reactive piperazinyl iminium intermediates have been identified as concerns for clinical translation and have motivated the development of next-generation analogs (LDN-212854, LDN-214117, ML347, DMH1, K02288) with improved selectivity or metabolic profiles. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Levosimendan

    Calcium sensitizer with phosphodiesterase III inhibition and ATP-sensitive potassium channel activation

    A pyridazinone-dinitrile inodilator developed at Orion Corporation as a calcium-sensitizing positive inotrope for acutely decompensated heart failure, distinguished from conventional inotropes by its ability to enhance myocardial contractility without increasing intracellular calcium concentration or myocardial oxygen consumption, and by its long-lived active metabolite OR-1896 that sustains hemodynamic effects for days beyond infusion cessation.

    Abstract

    Levosimendan, the (R)-enantiomer of simendan, is a pyridazinone-derivative calcium sensitizer and positive inotropic agent developed by Orion Corporation (Finland) and approved in approximately 60 countries for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not considered adequate. The compound exerts its principal pharmacological effects through three complementary mechanisms: calcium-dependent binding to the N-terminal domain of cardiac troponin C, which stabilizes the calcium-troponin C interaction and enhances myofilament sensitivity to calcium without increasing intracellular calcium concentration; selective inhibition of phosphodiesterase III (PDE3) in cardiac and vascular smooth muscle, which elevates cyclic adenosine monophosphate and contributes to positive inotropy and vasodilation; and opening of ATP-sensitive potassium channels (both sarcolemmal and mitochondrial) in vascular smooth muscle and cardiomyocytes, producing peripheral and coronary vasodilation and conferring cardioprotective effects against ischemia-reperfusion injury. The composite pharmacology produces the characteristic inodilator profile: simultaneous enhancement of cardiac contractility, reduction of cardiac preload and afterload, and improvement in coronary perfusion, all achieved without a proportional increase in myocardial oxygen demand.

    The pharmacokinetic profile of levosimendan is distinguished by the formation of an active metabolite, OR-1896, through intestinal reduction of the parent compound to the amino-derivative OR-1855 followed by hepatic N-acetylation. OR-1896 exhibits calcium-sensitizing and PDE3-inhibitory activity comparable to the parent compound and possesses an elimination half-life of approximately 75 to 80 hours in heart failure patients, compared to approximately 1 hour for the parent. This metabolite formation pathway introduces N-acetyltransferase 2 (NAT2) acetylator phenotype as a determinant of OR-1896 exposure, with slow acetylators demonstrating lower OR-1896 concentrations and potentially diminished sustained hemodynamic effects. The prolonged activity of OR-1896 sustains hemodynamic improvement for 7 to 9 days following cessation of a standard 24-hour intravenous infusion, a property unique among clinically available inotropic agents.

    The clinical evidence base comprises six principal Phase II and Phase III randomized controlled trials (LIDO, RUSSLAN, CASINO, REVIVE-I, REVIVE-II, SURVIVE) enrolling more than 3,000 patients with acute decompensated heart failure, supplemented by extensive registry data, meta-analyses, and ongoing investigation in cardiac surgery, cardiogenic shock, septic cardiomyopathy, pulmonary hypertension, right ventricular failure, and advanced heart failure with intermittent ambulatory infusion protocols. The LIDO trial demonstrated hemodynamic superiority and a 31-day survival advantage over dobutamine. The SURVIVE trial, the largest randomized comparison (1,327 patients), demonstrated superior reduction in B-type natriuretic peptide but did not achieve the primary endpoint of reduced 180-day all-cause mortality compared to dobutamine, though subgroup analyses favored levosimendan in patients on chronic beta-blocker therapy and those with prior heart failure history. Levosimendan is marketed as Simdax (Orion Corporation) and is not approved by the United States Food and Drug Administration; the original new drug application was withdrawn in 1999 following a request for additional trials. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Olpasiran

    N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting hepatic LPA messenger RNA for lipoprotein(a) reduction

    A synthetic, chemically modified, GalNAc-conjugated siRNA developed by Arrowhead Pharmaceuticals and licensed to Amgen that silences hepatic LPA gene expression through RNA interference, producing sustained and near-complete reduction of circulating lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease.

    Abstract

    Olpasiran (AMG 890; formerly ARO-LPA) is an investigational, first-in-class, synthetic double-stranded small interfering RNA (siRNA) conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand for selective hepatocyte delivery via the asialoglycoprotein receptor (ASGPR). The compound targets the messenger RNA transcribed from the LPA gene, which encodes apolipoprotein(a), the defining protein component of lipoprotein(a) [Lp(a)]. Elevated Lp(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic valve stenosis, and thrombotic events, affecting an estimated 20 to 30 percent of the global population at concentrations associated with increased cardiovascular risk. Prior to the development of RNA-targeted therapies, no pharmacologic intervention produced clinically meaningful reduction in Lp(a) concentration; niacin and PCSK9 inhibitors achieve modest decreases of 20 to 30 percent, insufficient to test the causal hypothesis relating Lp(a) lowering to cardiovascular event reduction.

    Following uptake into hepatocytes through ASGPR-mediated endocytosis, the antisense strand of olpasiran incorporates into the RNA-induced silencing complex (RISC), which catalytically cleaves LPA mRNA and suppresses de novo synthesis of apolipoprotein(a). The resulting reduction in hepatic apolipoprotein(a) secretion produces a dose-dependent, sustained, and near-complete lowering of circulating Lp(a) particles. In the Phase 1 single ascending-dose trial (NCT03626662), olpasiran produced dose-dependent Lp(a) reductions of 71 to 97 percent that persisted for several months after a single subcutaneous injection, with effects lasting up to six months at higher doses [1].

    The serum pharmacokinetics of olpasiran are characterized by rapid absorption after subcutaneous injection (time to maximum concentration approximately 3 to 9 hours) and rapid clearance from the systemic circulation (serum half-life approximately 3 to 8 hours), consistent with efficient hepatocyte uptake via the GalNAc-ASGPR pathway. The pharmacodynamic effect is dissociated from serum drug concentrations: the prolonged Lp(a) lowering reflects the intracellular persistence of the active RISC complex in hepatocytes rather than circulating drug exposure. The compound is well tolerated. In the OCEAN(a)-DOSE trial, the overall incidence of adverse events was similar in the olpasiran and placebo arms; the most frequently reported treatment-related adverse event was mild injection-site pain, which resolved without intervention [2]. No clinically significant changes in hepatic, renal, hematologic, or glycemic laboratory parameters were observed.

    Olpasiran is currently under evaluation in the Phase 3 OCEAN(a)-Outcomes trial (NCT05581303), a large cardiovascular outcomes study assessing the effect of olpasiran versus placebo on the composite endpoint of coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with ASCVD and elevated Lp(a). An additional Phase 3 primary prevention trial, OCEAN(a)-PreEvent (NCT07136012), is evaluating olpasiran for prevention of first major cardiovascular events. The compound is not approved by any regulatory authority as of the date of this monograph. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.